Nitrogen ( DrugBank: Nitrogen )

5 diseases

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008959	2012/11/01	16/10/2012	Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy	Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in MSA and PSP	Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP)	hydrogen water pseudo-water (nitrogen filling water)	Juntendo University School of Medicine, Department of Neurology	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	40	Phase 1	Japan

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000010014	2013/02/28	13/02/2013	Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease	Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease - Randomized Double-blind, Placebo-controlled trial on hydrogen water in Parkinson Disease	Parkinson's disesase	hydrogen water made by "Suisosui5.0" placebo-water (nitrogen filling water)	Juntendo University School of Medicine, Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	200	Not selected	Japan

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008959	2012/11/01	16/10/2012	Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy	Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in MSA and PSP	Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP)	hydrogen water pseudo-water (nitrogen filling water)	Juntendo University School of Medicine, Department of Neurology	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	40	Phase 1	Japan

臨床試験数 : 22 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000017311	2015/05/01	01/05/2015	Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease.	Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. - Hypoxia inhalation therapy for infants	hypoplastic left heart syndrome, coarctation of aorta, interruption of aorta, truncus arteriosus, double outlet of right ventricle (Taussig-Bing anomaly), single ventricles	Hypoxia inhalation nitrogen inhalation	Institutional Review Board of Kagoshima University	NULL	Pending	1days-old	365days-old	Male and Female	30	Not selected	Japan

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00570349 (ClinicalTrials.gov)	July 2004	6/12/2007	Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Nitric Oxide for Inhalation;Drug: Nitrogen	Mallinckrodt	NULL	Completed	12 Years	N/A	All	18	Phase 1/Phase 2	United States